Launched in 2010, EBRI's Center for Research on Health Benefits Innovation (CRHBI) focuses on helping employers assess the impact that various innovations, such as through plan design and other initiatives, have on cost, quality, and access to health care. It is a think tank focused on three broad areas of research: behavioral economics, incentives, and consumer-driven health benefits. This understanding, in turn, provides a framework for solutions and action items to address the cost and value of providing health benefits and informs policy discussions that can also best help improve outcomes.
The Center focuses on three broad areas of research.
The Center is funded by the following Research Partners:
These organizations also form the Center's advisory board. The advisory board sets the research agenda, determines research priorities within the constraints of available funding, and assists in data acquisition.
For more information about the research center, participation on the advisory board, and/or funding, contact Paul Fronstin, Chair of the Center.
Wellness Programs: Workplace wellness programs appear to have a bigger impact on medication adherence for some diseases than others, according to new research from EBRI. Press release.
Single/Couple Households: Older singles and older couples tend to face sharply different out-of-pocket expenses for non-recurring health care services such as home health care, nursing home stays, overnight hospital stays, and outpatient surgery—possibly because they do not have a spouse to help as caregivers, according to new research by EBRI. Press release.
Prescription Drug Use: Do consumer-directed health plans (CDHPs) result in lower prescription drug use? New research from EBRI of one big employer finds that moving to an HSA-eligible plan reduced the number of both generic and brand-name prescriptions filled.
Lifetime Income Illustrations: Do consumer-directed health plans (CDHPs) result in lower prescription drug use? New research from EBRI of one big employer finds that moving to an HSA-eligible plan reduced the number of both generic and brand-name prescriptions filled.